AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 498955 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy producing complete clinical remission
Number of subjects: 182
Study 498955 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploratory laparotomy with splenectomy
Number of subjects: 182
Study 498955 — intervention group
Group type: COMPARATOR
Intervention: Clinical stage III patients
Number of subjects: 182
Study 31868879 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy followed by radical hysterectomy
Number of subjects: 0
Study 31868879 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemoradiotherapy
Number of subjects: 0
Study 31868879 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical hysterectomy followed by adjuvant radiotherapy
Number of subjects: 0
Study 31868879 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality strategy consisting of radical hysterectomy/perioperative chemotherapy
Number of subjects: 0
Study 31095683 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered individual treatment (SIT)
Number of subjects: 0
Study 31095683 — intervention group
Group type: EXPERIMENTAL
Intervention: Group treatment (GT)
Number of subjects: 0
Study 31095683 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT)
Number of subjects: 0
Study 31095683 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 0
Study 28796687 — intervention group
Group type: EXPERIMENTAL
Intervention: Poliglecaprone 25 suture
Number of subjects: 550
Study 28796687 — intervention group
Group type: COMPARATOR
Intervention: Polyglactin 910 suture
Number of subjects: 550
Study 26470422 — intervention group
Group type: EXPERIMENTAL
Intervention: Longidaze in addition to standard etiotropic antibacterial therapy
Number of subjects: 0
Study 26470422 — intervention group
Group type: COMPARATOR
Intervention: Standard etiotropic antibacterial therapy
Number of subjects: 0
Study 23357198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×10(10) IU of the vaccine
Number of subjects: 42
Study 23357198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×10(9) IU of the vaccine
Number of subjects: 42
Study 23357198 — intervention group
Group type: EXPERIMENTAL
Intervention: 1×10(8) IU of the vaccine
Number of subjects: 42
Study 23357198 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 20689977 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral group therapy (CBT)
Number of subjects: 174
Study 20689977 — intervention group
Group type: COMPARATOR
Intervention: Client-centered, supportive-experiential group therapy (SET)
Number of subjects: 174
Study 19240109 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac Resynchronization Therapy (CRT)
Number of subjects: 87
Study 17874015 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Positive Pressure Breathing (IPPB)
Number of subjects: 40
Study 17874015 — intervention group
Group type: COMPARATOR
Intervention: Incentive Spirometry (IS)
Number of subjects: 40
Study 15466071 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH (0.025-0.04 mg/kg per day) plus conventional therapy
Number of subjects: 8
Study 11495269 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosol therapy (streptomycin and steroids)
Number of subjects: 57
Study 11495269 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 57
Study 9692657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 23
Study 9692657 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg every other day
Number of subjects: 23
Study 9692657 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 23
Study 7873824 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral itraconazole 200 mg daily for 7 days
Number of subjects: 153
Study 7873824 — intervention group
Group type: COMPARATOR
Intervention: Oral itraconazole 100 mg for 15 days
Number of subjects: 153
Study 3145677 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboprost (15‐methyl PGF2 alpha) administered 8 hours after ethacridine lactate instillation
Number of subjects: 0
Study 3145677 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboprost (15‐methyl PGF2 alpha) administered 4 hours after ethacridine lactate instillation
Number of subjects: 0
Study 3145677 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboprost (15‐methyl PGF2 alpha) administered 2 hours after ethacridine lactate instillation
Number of subjects: 0
Study 31845611 — intervention group
Group type: EXPERIMENTAL
Intervention: EEGer neurofeedback software used for treatment
Number of subjects: 0
Study 31845611 — intervention group
Group type: COMPARATOR
Intervention: Thought Technology Monastra‐Lubar Assessment Suite
Number of subjects: 0
Study 30061276 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) - single-fraction 24 Gy
Number of subjects: 55
Study 30061276 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT) - 30 Gy/10 fractions
Number of subjects: 55
Study 30061276 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 55
Study 30061276 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3DCRT)
Number of subjects: 55
Study 27081177 — intervention group
Group type: EXPERIMENTAL
Intervention: pomalidomide + low-dose dexamethasone
Number of subjects: 447
Study 27081177 — intervention group
Group type: COMPARATOR
Intervention: high-dose dexamethasone
Number of subjects: 447
Study 25757358 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based psychotherapy
Number of subjects: 43
Study 23747759 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg in very elderly patients
Number of subjects: 155
Study 23747759 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel 10 mg in nonelderly patients
Number of subjects: 155
Study 23747759 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg in very elderly patients
Number of subjects: 155
Study 20884923 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 minutes application time
Number of subjects: 60
Study 20884923 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 minutes application time
Number of subjects: 60
Study 20884923 — intervention group
Group type: EXPERIMENTAL
Intervention: One hour application time
Number of subjects: 60
Study 20884923 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight hours application time
Number of subjects: 60
Study 18510659 — intervention group
Group type: EXPERIMENTAL
Intervention: tolterodine ER (4 mg) + tamsulosin (0.4 mg)
Number of subjects: 0
Study 18510659 — intervention group
Group type: EXPERIMENTAL
Intervention: tamsulosin (0.4 mg)
Number of subjects: 0
Study 18510659 — intervention group
Group type: COMPARATOR
Intervention: tolterodine ER (4 mg)
Number of subjects: 0
Study 18510659 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study 15725881 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniotic membrane graft (AMG) alone
Number of subjects: 94
Study 15725881 — intervention group
Group type: COMPARATOR
Intervention: Amniotic membrane graft (AMG) combined with intraoperative 0.025% mitomycin C
Number of subjects: 94
Study 12466173 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular buckling procedure
Number of subjects: 10
Study 10620155 — intervention group
Group type: EXPERIMENTAL
Intervention: Pin-retained amalgam
Number of subjects: 32
Study 10620155 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam with a meta adhesive
Number of subjects: 32
Study 10620155 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin with a beta-glass quartz insert
Number of subjects: 32
Study 10620155 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin with a HEMA adhesive
Number of subjects: 32
Study 7613636 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (screening)
Number of subjects: 0
Study 7613636 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 0
Study 7613636 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall mortality analyses
Number of subjects: 0
Study 7613636 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited mortality analyses
Number of subjects: 0
Study 2143596 — intervention group
Group type: EXPERIMENTAL
Intervention: Triatec 2.5 mg
Number of subjects: 770
Study 2143596 — intervention group
Group type: EXPERIMENTAL
Intervention: Triatec 5 mg
Number of subjects: 770
Study 2143596 — intervention group
Group type: EXPERIMENTAL
Intervention: Triatec 10 mg
Number of subjects: 770
Study 2143596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 20 mg Lasilix and Triatec 5 mg
Number of subjects: 770
Study 2143596 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment plan
Number of subjects: 770
Study 7449282 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 57
Study 7449282 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 57
Study 7449282 — intervention group
Group type: EXPERIMENTAL
Intervention: Bed rest
Number of subjects: 57
Study 7449282 — intervention group
Group type: COMPARATOR
Intervention: Control (normotensive patients)
Number of subjects: 57
Study 7449282 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive patients
Number of subjects: 57
Study 31715583 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback during small-sided games
Number of subjects: 20
Study 31715583 — intervention group
Group type: COMPARATOR
Intervention: No feedback (control) during small-sided games
Number of subjects: 20
Study 29993709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Frequent Directions Algorithm with Sparse Subspace Embedding (SpEmb)
Number of subjects: 0
Study 29993709 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast Frequent Directions Algorithm
Number of subjects: 0
Study 28783382 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-generation antipsychotics (SGAs)
Number of subjects: 35
Study 25596468 — intervention group
Group type: EXPERIMENTAL
Intervention: Early invasive strategy (tirofiban infusion and coronary angiography within 6h)
Number of subjects: 170
Study 25596468 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy (coronary angiography not advised within 6h)
Number of subjects: 170
Study 25596468 — intervention group
Group type: COMPARATOR
Intervention: Delayed invasive strategy
Number of subjects: 170
Study 25596468 — intervention group
Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 170
Study 23996046 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous short-segment pedicle screw internal fixation with PKP
Number of subjects: 43
Study 23996046 — intervention group
Group type: COMPARATOR
Intervention: Simple PKP (control group)
Number of subjects: 43
Study 21256149 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Intervention (SI) - targeted print intervention by mail
Number of subjects: 1430
Study 21256149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention (TI) - targeted intervention and tailored message pages
Number of subjects: 1430
Study 21256149 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Intervention plus Phone (TIP) - targeted intervention, tailored message pages, and a telephone reminder
Number of subjects: 1430
Study 21256149 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care)
Number of subjects: 1430
Study 19380393 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular abdominal aortic aneurysm repair (EVAR)
Number of subjects: 0
Study 19380393 — intervention group
Group type: COMPARATOR
Intervention: Open aneurysm repair (OAR)
Number of subjects: 0
Study 17876916 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate pretreatment
Number of subjects: 84
Study 17876916 — intervention group
Group type: COMPARATOR
Intervention: Suxamethonium without magnesium sulphate pretreatment
Number of subjects: 84
Study 15052217 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery (CABG)
Number of subjects: 12079
Study 12575397 — intervention group
Group type: EXPERIMENTAL
Intervention: Bitongxiao (BTX)
Number of subjects: 102
Study 12575397 — intervention group
Group type: COMPARATOR
Intervention: Jingfukang (JFK) granule (Control)
Number of subjects: 102
Study 12575397 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 102
Study 11083217 — intervention group
Group type: EXPERIMENTAL
Intervention: Instruction
Number of subjects: 12
Study 11083217 — intervention group
Group type: COMPARATOR
Intervention: Passive observation
Number of subjects: 12
Study 9192504 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous salmon calcitonin (SCSCT) 50 IU/day for 30 days
Number of subjects: 204
Study 9192504 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal salmon calcitonin (INSCT) 200 IU/day for 30 days
Number of subjects: 204
Study 9192504 — intervention group
Group type: COMPARATOR
Intervention: Both formulations
Number of subjects: 204
Study 9192504 — intervention group
Group type: COMPARATOR
Intervention: INSCT
Number of subjects: 204
Study 1549989 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency medical system transport with prehospital 12-lead ECG
Number of subjects: 4
Study 1549989 — intervention group
Group type: COMPARATOR
Intervention: Emergency medical system transport without prehospital ECG
Number of subjects: 4
Study 1549989 — intervention group
Group type: COMPARATOR
Intervention: Local ambulance transport
Number of subjects: 4
Study 1549989 — intervention group
Group type: COMPARATOR
Intervention: Private automobile transport (walk-in)
Number of subjects: 4
Study 3905052 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment in low-risk tercile (VA population)
Number of subjects: 0
Study 3905052 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment in high-risk tercile (VA population)
Number of subjects: 0
Study 3905052 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment in CASS
Number of subjects: 0
Study 3905052 — intervention group
Group type: COMPARATOR
Intervention: Surgical treatment in CASS
Number of subjects: 0
Study 29329698 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise training (MS-EX) for 8 weeks
Number of subjects: 36
Study 29329698 — intervention group
Group type: COMPARATOR
Intervention: Control group (MS-C)
Number of subjects: 36
Study 26896456 — intervention group
Group type: EXPERIMENTAL
Intervention: sarolaner (Simparica™) 2-4 mg/kg
Number of subjects: 24
Study 26896456 — intervention group
Group type: EXPERIMENTAL
Intervention: afoxolaner (NexGard®) 2.5-6.8 mg/kg
Number of subjects: 24
Study 26896456 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study 24497345 — intervention group
Group type: EXPERIMENTAL
Intervention: CD133(+) BMC injection
Number of subjects: 60
Study 24497345 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 60
Study 22582693 — intervention group
Group type: EXPERIMENTAL
Intervention: Orienteering lessons for 6 months
Number of subjects: 20
Study 22582693 — intervention group
Group type: COMPARATOR
Intervention: Jogging training
Number of subjects: 20
Study 20215545 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib (1,500 mg once daily or 500 mg twice daily)
Number of subjects: 75
Study 18831352 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/day buprenorphine
Number of subjects: 23
Study 18831352 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day buprenorphine
Number of subjects: 23
Study 16019973 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 0
Study 16019973 — intervention group
Group type: EXPERIMENTAL
Intervention: LAAM
Number of subjects: 0
Study 16019973 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 0
Study 16019973 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine, LAAM, Methadone
Number of subjects: 0
Study 11843073 — intervention group
Group type: EXPERIMENTAL
Intervention: Head injury
Number of subjects: 82
Study 11843073 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttraumatic stress
Number of subjects: 82
Study 11843073 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 82
Study 11843073 — intervention group
Group type: COMPARATOR
Intervention: Orthopedic injury
Number of subjects: 82
Study 10402974 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 malaria vaccine
Number of subjects: 1207
Study 10402974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1207
Study 7743739 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental questionnaires (specific questionnaires not detailed)
Number of subjects: 97
Study 7743739 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient preference scales
Number of subjects: 97
Study 7743739 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire on performance in various roles in life
Number of subjects: 97
Study 7743739 — intervention group
Group type: COMPARATOR
Intervention: IRGL questionnaire
Number of subjects: 97
Study 2103759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60 mg t.d.s.)
Number of subjects: 8
Study 2103759 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2103759 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 8
Study 30897567 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Point Therapy (PPT) - 10 units of 10 min each
Number of subjects: 80
Study 30897567 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy - 10 units of 30 min each
Number of subjects: 80
Study 30897567 — intervention group
Group type: EXPERIMENTAL
Intervention: Power Point Therapy (PPT)
Number of subjects: 80
Study 30897567 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 80
Study 28940353 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 6000 mg/day for 28 days
Number of subjects: 8
Study 27423164 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure and Response Prevention (EX/RP)
Number of subjects: 70
Study 27423164 — intervention group
Group type: COMPARATOR
Intervention: Open treatment following nonresponse to risperidone or placebo
Number of subjects: 70
Study 25273659 — intervention group
Group type: EXPERIMENTAL
Intervention: No nasogastric intubation and early oral feeding (trial group)
Number of subjects: 316
Study 25273659 — intervention group
Group type: COMPARATOR
Intervention: Routine management (control group)
Number of subjects: 316
Study 22886837 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac 18.75 mg
Number of subjects: 331
Study 22886837 — intervention group
Group type: EXPERIMENTAL
Intervention: HPβCD diclofenac 37.5 mg
Number of subjects: 331
Study 22886837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 30 mg
Number of subjects: 331
Study 22886837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 331
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting details of trial participants
Number of subjects: 345
Study 20615225 — intervention group
Group type: COMPARATOR
Intervention: Chinese abstracts reporting control group intervention
Number of subjects: 345
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting number of participants randomized
Number of subjects: 345
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting benefits when interpreting trial results
Number of subjects: 345
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting trial design details
Number of subjects: 345
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese abstracts defining primary outcome
Number of subjects: 345
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese abstracts describing methods of random sequence generation
Number of subjects: 345
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese abstracts reporting number of participants analyzed
Number of subjects: 345
Study 20615225 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage agreement in reporting between Chinese and English versions
Number of subjects: 345
Study 18511049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod with whole-dose PEG-E
Number of subjects: 382
Study 18511049 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod with split-dose PEG-E
Number of subjects: 382
Study 18511049 — intervention group
Group type: COMPARATOR
Intervention: Placebo with whole-dose PEG-E
Number of subjects: 382
Study 18511049 — intervention group
Group type: COMPARATOR
Intervention: Placebo with split-dose PEG-E
Number of subjects: 382
Study 18511049 — intervention group
Group type: COMPARATOR
Intervention: Whole-dose PEG-E
Number of subjects: 382
Study 18511049 — intervention group
Group type: EXPERIMENTAL
Intervention: Split-dose PEG-E
Number of subjects: 382
Study 18511049 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 382
Study 21961341 — intervention group
Group type: COMPARATOR
Intervention: One insemination at 36 hours after hCG
Number of subjects: 138
Study 21961341 — intervention group
Group type: EXPERIMENTAL
Intervention: Two inseminations at 24 and 48 hours after hCG
Number of subjects: 138
Study 21961341 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ovulatory dysfunction
Number of subjects: 138
Study 21961341 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with endometriosis
Number of subjects: 138
Study 12534959 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 15
Study 12534959 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium gluconate/calcium carbonate
Number of subjects: 15
Study 12534959 — intervention group
Group type: COMPARATOR
Intervention: Calcium supplements
Number of subjects: 15
Study 10967229 — intervention group
Group type: EXPERIMENTAL
Intervention: Flashing red lights as elements with apparent movement as a unique cue in experiment 1
Number of subjects: 0
Study 10967229 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual frame surrounding letter stimuli in experiment 2
Number of subjects: 0
Study 8872728 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of nitrendipine (Bypress; Bayer) 2 hours before SWL
Number of subjects: 20
Study 8872728 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 20